BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

cafead

Administrator
Staff member
  • cafead   Jan 16, 2020 at 11:32: PM
via Speaking at an interview at the J.P Morgan Healthcare Conference that's going on right now, BioMarin Pharmaceutical's (NASDAQ:BMRN) CEO Jean-Jacques Bienaimé went on to say that the company was considering a hefty $2 million to $3 million dollar price tag for its hemophilia treatment, Valrox.

article source
 

<